<unk>  (development name, AA-2414; marketed originally as Bronica) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997. As of 2017<unk>  was marketed as Bronica in Japan, and as Changnuo, Mai Xu Jia, Quan Kang Nuo in China. Unlike thromboxane synthase inhibitors such as ozagrel,<unk>  does not affect thrombus formation, time to occlusion and bleeding time.<unk>  has no effect on prothrombin time and activated partial thromboplastin time, thus ruling out any action on blood coagulation cascade.
Seratrodast
Montelukast
Azelastine
Lifitegrast
Allergan
Pemirolast
Pranlukast
Roxadustat